Navigation Links
Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress

Nasalfent shows clinically meaningful pain relief within 5 minutes of dosing and is well-tolerated

READING, England, 7 June 2007 - Archimedes Pharma Ltd ("Archimedes"), a European specialty pharmaceutical company, today presented new clinical data from a Phase II study of Nasalfent(r), an innovative fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain. Data were presented at the 10th Congress of the European Association for Palliative Care (EAPC) in Budapest showing that Nasalfent can give significant, clinically meaningful levels of pain relief and a reduction in pain intensity within 5 minutes of dosing.

The open-label, multi-centre study, was conducted in two parts - the first to establish an effective dose for each patient, followed by an efficacy phase in which the dose identified in part one was evaluated using a series of measures for pain relief. Statistically significant improvements from baseline in pain intensity and onset of pain relief were seen within five minutes of dosing (both p<0.05) in the 15 patients included in the efficacy analysis. All patients experienced at least one episode with meaningful pain relief and in the 55 breakthrough cancer pain episodes assessed, some degree of pain relief was recorded in 96% and clinically meaningful pain relief in 73%.

All doses of Nasalfent from 25mcg to 800mcg were well-tolerated, with no significant nasal findings or symptoms of irritation seen at any dose. In a patient satisfaction survey, 77% rated the product as 'good', 'very good' or 'excellent'.

Principal Investigator Dr Geoff Davis, Medical Director of Palliative Care, St Joseph's Care Group, Thunder Bay, Ontario, Canada said: "Breakthrough cancer pain is a significant clinical problem which requires a drug with a fast and reliable onset of action, together with ease of use and high patient acceptabilit
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/29/2014)... DIEGO, July 29, 2014  Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, today reported total revenues of $39.8 ... of 62% compared to revenues of $24.5 million for ... Bioscience business segment, which was sold on May 30, ... and consequently its results have been excluded from continuing ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 /PRNewswire/ ... today that it is participating in two healthcare conferences ... 1-1 Conference and the Morgan Stanley Global Healthcare 2014 ... the Morgan Stanley Conference.  The details on each event ... 1-1 Conference, Monday, August 11, 2014 in ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19
... Mass., Feb. 15, 2011 Echo Therapeutics, Inc. (OTC ... the Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced the appointment ... its Board of Directors.  Echo,s Board now has a ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... announced that they have entered into a research agreement ... treat chronic wounds. This includes neuropathic diabetic foot ulcers ... that are complicated by peripheral arterial disease, commonly called ...
Cached Medicine Technology:Echo Therapeutics Announces Appointments to Board of Directors 2Echo Therapeutics Announces Appointments to Board of Directors 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 2Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 4
(Date:7/29/2014)... electroacupuncture (EA) a form of acupuncture where ... of acupuncture needles produces significant improvements in ... eight weeks for early stage breast cancer patients ... aromatase inhibitors (AIs) to treat breast cancer. The ... intervention led by researchers at the Perelman School ...
(Date:7/29/2014)... 2014 Diabetes is a common condition diagnosed ... sugar levels are increased, while the production of insulin is ... pancreas and which is needed by the body to regulate ... can be very dangerous, as there are numerous complications that ... about this disorder and read a complex review of Matt ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 DailyGossip.org reveals ... this actually is a new method of naturally overcoming ... author of the new method ensure sufferers that the ... right recommendations. , The new method is described ... completely overcome sciatica with an 8 minutes per day ...
(Date:7/29/2014)... Recent international changes to the ... Nurse Call Systems to be considered medical devices. ... Nurse Call Systems to be clinically regulated, audited ... reduces clinical risks, and is good news for ... and Clinical Risk Committee actively pursuing corporate governance. ...
(Date:7/29/2014)... Regardless of the good things that ... to share those with. Love is about understanding, commitment ... Love is also about overcoming all the challenges that ... perfect relationship, women need to know how to understand ... Him program, please visit the official website at ...
Breaking Medicine News(10 mins):Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2
... Jan. 3 (HealthDay News) -- Parents can involve their children ... the works, says one fitness expert, by making exercise seem ... take the kids out for a walk this evening, most ... the video games or television?," cautioned Michael Berry, chair of ...
... diagnosed with schizophrenia and other psychoses appear to show ... cerebrospinal fluid in the frontal lobe compared to healthy ... report in the January issue of Archives of ... "Progressive loss of brain gray matter (GM) has been ...
... from visceral fat called adiponectin may play a role as ... disease (AD) in women, according to a study published Online ... the JAMA/Archives journals. The number of people affected by ... years from the current number of about 36 million people, ...
... HealthDay Reporter , MONDAY, Jan. 2 (HealthDay ... leaves people feeling good about themselves and positive about ... mean practicing random acts of kindness has scientifically proven ... Yes, according to a growing body of research that ...
... FRIDAY, Dec. 30 (HealthDay News) -- Researchers have identified ... for developing the thyroid cancer, with one in particular ... for the disease. Dr. Charis Eng, founding director ... Research Institute, said in a news release that her ...
... News) --,Overcrowding in emergency rooms appears to keep children ... in a timely manner, according to a new study. ... Medicine said their findings are significant since these injuries, ... and very painful. "Pain associated with long bone ...
Cached Medicine News:Health News:Fun Ways to Include Kids in Fitness Resolutions 2Health News:Schizophrenia diagnosis associated with progressive brain changes among adolescents 2Health News:Study finds another potential risk factor for developing dementia and Alzheimer's disease in women 2Health News:With Depression, Helping Others May in Turn Help You 2Health News:With Depression, Helping Others May in Turn Help You 3Health News:Gene Mutations Linked to Thyroid Cancer Risk: Study 2Health News:Crowding in ER May Delay Pain Relief for Kids 2
... dedicated fluorometer from Berthold Technologies, has ... variety of measurement modes to support ... scanning, dual ratio measurements plus top ... valuable instrument for any researcher using ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
Small, compact and versatile, the CLK-4 light source is compatible with all Olympus fiberscopes and is ideal for the vast majority of routine fiber-endoscopic procedures, especially in the out-patien...
Medicine Products: